OTC: PPCB - Propanc Biopharma, Inc.

六个月盈利: -83.33%
部门: Healthcare

促销时间表 Propanc Biopharma, Inc.


关于公司

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.

更多详情
The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

ISIN US74346N4043
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.propanc.com
Цена ао 0.0027
每日价格变化: 0% (0.0002)
每周价格变化: 0% (0.0002)
每月价格变化: -33.33% (0.0003)
3个月内价格变化: -33.33% (0.0003)
六个月内的价格变化: -83.33% (0.0012)
每年价格变化: -98.33% (0.012)
3年内价格变化: -98.89% (0.018)
5年内价格变化: -99.94% (0.35)
10年价格变化: 0% (0.0002)
年初以来价格变化: 0% (0.0002)

低估

姓名 意义 年级
P/S 0 0
P/BV -0.0248 0
P/E 0 0
EV/EBITDA -0.6645 0
全部的: 2.5

效率

姓名 意义 年级
ROA, % -2743.97 0
ROE, % 52.8 10
全部的: 3.33

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.6173 10
全部的: 6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % -50.45 0
盈利能力 EPS, % -99.88 0
全部的: 0



导师 职称 支付 出生年份
Mr. James Nathanielsz Executive Chairman, CEO, CFO, Treasurer & Secretary 430.28k 1974 (51 年)
Dr. Julian Norman Kenyon ChB, M.D., MB Chief Scientific Officer, CTO & Director 35.99k 1948 (77 年)
Prof. Klaus Kutz Chief Medical Officer & Member of Scientific Advisory Board 18.23k

地址: Australia, Camberwell. VIC, 302. 6 Butler Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.propanc.com